Theravance Biopharma Inc (0TB) — Cash Flow-to-Debt Ratio
Theravance Biopharma Inc (0TB) has a Cash Flow-to-Debt Ratio of -0.04x as of September 2025, meaning its operating cash flow of €-6.51 Million could theoretically repay 0% of its total liabilities (€182.78 Million) in one year. Explore Theravance Biopharma Inc (0TB) investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Theravance Biopharma Inc Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for Theravance Biopharma Inc across 11 annual periods. Also explore Theravance Biopharma Inc balance sheet assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Theravance Biopharma Inc (2014–2024)
Year-by-year debt coverage analysis for Theravance Biopharma Inc. For market capitalisation and broader financial context, see 0TB market cap.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.06x | €-11.54 Million | €178.62 Million | ▲ +59.6% |
| 2023 | -0.16x | €-27.00 Million | €169.00 Million | ▲ +85.9% |
| 2022 | -1.13x | €-186.99 Million | €165.60 Million | ▼ -287.5% |
| 2021 | -0.29x | €-207.86 Million | €713.39 Million | ▲ +10.1% |
| 2020 | -0.32x | €-250.40 Million | €772.81 Million | ▲ +13.9% |
| 2019 | -0.38x | €-238.20 Million | €632.67 Million | ▼ -104.1% |
| 2018 | -0.18x | €-112.87 Million | €611.82 Million | ▲ +70.1% |
| 2017 | -0.62x | €-201.05 Million | €326.22 Million | ▼ -79.9% |
| 2016 | -0.34x | €-98.99 Million | €289.02 Million | ▲ +88.4% |
| 2015 | -2.96x | €-168.86 Million | €57.05 Million | ▲ +18.9% |
| 2014 | -3.65x | €-175.16 Million | €47.98 Million | — |